Evaluation of valganciclovir's neutropenia risk in pediatric solid organ transplant recipients utilizing two dosing regimens

Author:

Patel Avani1,Le Kevin2,Panek Natalia2ORCID

Affiliation:

1. The Children's Hospital of Philadelphia Philadelphia Pennsylvania USA

2. Ann & Robert H. Lurie Children's Hospital of Chicago Chicago Illinois USA

Abstract

AbstractBackgroundValganciclovir is approved for cytomegalovirus prophylaxis in pediatrics using the Pescovitz algorithm. There are reports of valganciclovir overdoses in children with low body surface area and overestimated creatinine clearance utilizing this algorithm. This study compared the incidence of neutropenia and cytomegalovirus infection between the Pescovitz and weight‐based dosing algorithms.MethodsA single‐center retrospective chart review from January 2010 to September 2018 was performed on pediatric heart, liver, and kidney transplant recipients, who received valganciclovir. Data were collected from the initiation of valganciclovir prophylaxis to 30 days after discontinuation. The primary objective was the incidence of neutropenia in patients receiving valganciclovir dosed by the Pescovitz versus weight‐based dosing algorithms.ResultsThis study included 187 pediatric transplant recipients who received valganciclovir dosed via the Pescovitz (62 recipients) or weight‐based dosing algorithms (125 recipients). The incidence of neutropenia was higher in the Pescovitz (69.4%) compared to the weight‐based dosing group (53.6%; p = .04) including moderate and severe neutropenia. Cytomegalovirus viremia was not significantly different between the two groups and occurred in 4.8% of the Pescovitz group compared to 2.4% of the weight‐based group (p = .4).ConclusionsThe incidence of neutropenia was greater in recipients receiving valganciclovir dosed via the Pescovitz algorithm compared to the weight‐based dosing. There were no significant differences in regard to cytomegalovirus viremia or disease between the two groups.

Publisher

Wiley

Reference9 articles.

1. A national survey of valganciclovir dosing strategies in pediatric organ transplant recipients

2. U.S. Food & Drug Administration.FDA Drug Safety Communication. U.S. Food & Drug Administration. FDA Drug Safety Communication.https://www.fda.gov/drugs/drug‐safety‐and‐availability/fda‐drug‐safety‐communication‐new‐dosing‐recommendations‐prevent‐potential‐valcyte‐valganciclovir. Accessed 2018 Aug 4.

3. Cytomegalovirus in solid organ transplant recipients—Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice

4. Measurement and Estimation of Glomerular Filtration Rate in Children

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3